Skip to main content
    S

    Sarepta Therapeutics Inc (SRPT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.83
    +0.32 (+1.94%)

    Market Cap: $1.77B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    49%(19/39)
    Avg Surprise
    +116.70%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.36
    Range$-0.06 - $1.04
    10 analysts
    EPS Revisions
    1
    0
    7d
    4
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$0.48-25.0%
    60d ago$0.39-6.8%
    30d ago$0.42-13.6%
    7d ago$0.37-2.4%
    Current$0.36
    Revenue Consensus
    $352M
    Range$322M - $392M
    18 analysts
    Period ending Dec 31, 2026
    EPS Consensus$2.43
    Range$0.98 - $3.96
    10 analysts
    Revenue Consensus
    $640M
    Range$589M - $722M
    20 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$2.43---
    Sep 26EST
    		-$0.36---
    Jun 26
    Reported Aug 5
    		$0.42$0.34+23.53%Beat-79.2%
    Mar 26
    Reported May 6
    		$3.16$1.05+200.95%Beat+192.4%
    Dec 25
    Reported Feb 25
    		$-3.58$-1.05-240.95%Miss-288.4%
    Sep 25
    Reported Nov 3
    		$-0.13N/A+64.86%Beat-121.0%
    Jun 25
    Reported Aug 6
    		$2.02$1.16+74.14%Beat+359.1%
    Mar 25
    Reported May 6
    		$-3.42$-0.65-426.15%Miss-568.5%
    Dec 24
    Reported Feb 26
    		$1.90$2.06-7.78%Miss+304.3%
    Sep 24
    Reported Nov 6
    		$0.62$0.37+67.57%Beat+67.6%
    Jun 24
    Reported Aug 7
    		$0.44$0.47-6.38%Miss+151.8%
    Mar 24
    Reported May 1
    		$0.73$0.41+78.05%Beat+175.3%
    Dec 23
    Reported Feb 28
    		$0.47$0.01+4600.00%Beat+137.9%
    Sep 23
    Reported Nov 1
    		$0.37$-0.49+175.51%Beat+146.3%
    Jun 23
    Reported Aug 2
    		$-0.85$-1.00+15.00%Beat+28.0%
    Mar 23
    Reported May 2
    		$-0.97$-0.83-16.87%Miss-73.2%
    Dec 22
    Reported Feb 28
    		$-1.24$-1.35+8.15%Beat+12.7%
    Sep 22
    Reported Nov 2
    		$-0.80$-0.74-8.11%Miss-321.1%
    Jun 22
    Reported Aug 2
    		$-1.18$-0.60-96.67%Miss+22.4%
    Mar 22
    Reported May 4
    		$-0.56$-1.03+45.63%Beat+63.6%
    Dec 21
    Reported Mar 1
    		$-1.42$-1.13-25.66%Miss+40.8%
    Sep 21
    Reported Nov 3
    		$-0.19N/A+87.50%Beat+86.6%
    Jun 21
    Reported Aug 4
    		$-1.52$-1.29-17.83%Miss-0.7%
    Mar 21
    Reported May 5
    		$-1.54$-1.57+1.91%Beat-569.6%
    Dec 20
    Reported Mar 1
    		$-2.40$-1.78-34.83%Miss-52.9%
    Sep 20
    Reported Nov 5
    		$-1.42$-1.40-1.43%Miss-24.6%
    Jun 20
    Reported Aug 5
    		$-1.51$-1.31-15.27%Miss-81.9%
    Mar 20
    Reported May 6
    		$-0.23N/A+87.77%Beat+69.3%
    Dec 19
    Reported Feb 26
    		$-1.57$-1.27-23.62%Miss+23.4%
    Sep 19
    Reported Nov 7
    		$-1.14$-0.92-23.91%Miss-103.6%
    Jun 19
    Reported Aug 7
    		$-0.83$-0.77-7.79%Miss-93.0%
    Mar 19
    Reported May 8
    		$-0.75$-0.81+7.41%Beat-167.9%
    Dec 18
    Reported Feb 27
    		$-2.05$-1.02-100.98%Miss-454.1%
    Sep 18
    Reported Oct 24
    		$-0.56$-0.49-14.29%Miss-69.7%
    Jun 18
    Reported Aug 8
    		$-0.43$-0.33-30.30%Miss+33.8%
    Mar 18
    Reported May 3
    		$-0.28$-0.24-16.67%Miss+53.3%
    Dec 17
    Reported Mar 1
    		$-0.37$-0.32-15.63%Miss+57.5%
    Sep 17
    Reported Oct 25
    		$-0.33N/A+57.14%Beat-
    Jun 17
    Reported Jul 19
    		$-0.65$-0.78+16.67%Beat-
    Mar 17
    Reported Apr 27
    		$-0.60$-0.94+36.17%Beat-
    Dec 16
    Reported Feb 28
    		$-0.87$-1.33+34.59%Beat-

    Key Metrics

    Valuation
    P/E Ratio-129.46EV/EBITDAN/A
    Price/FCF21.68xFCF Yield4.61%
    Profitability
    Profit Margin-6.93%Operating Margin13.00%
    ROE-9.48%ROIC-6.22%
    Financial Health
    Debt/Equity0.55xInterest CoverageN/A
    Current Ratio4.42xQuick Ratio2.62x
    Trading Statistics
    Beta0.38Avg Volume2.79M
    52-Week High$24.6852-Week Low$14.68

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.42
    SMA 20$18.38
    SMA 50$19.13
    SMA 200$18.95
    EMA 10$17.53
    EMA 20$18.17
    EMA 50$18.63
    EMA 200$19.94

    MACD

    Line: -0.71Signal: -0.55Hist: -0.16

    ADX

    ADX: 18.0+DI: 17.6-DI: 28.0

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$18.48

    Bollinger Bands

    Upper Band$20.86
    Lower Band$15.90
    %B Position2696%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    37.8

    Momentum Oscillators

    Stoch %K11.5
    Stoch %D14.8
    Williams %R-81.4
    ROC (10d)-7.6%
    Momentum-1.39
    CCI (20d)-115.9
    MFI (14d)29.3

    Volatility Measures

    ATR (14d)$0.95(5.7%)
    StdDev (20d)1.24
    Hist Vol51.3%(High)

    Volume Flow

    VWAP$16.70
    OBV-61.2M
    AD Line-116.2M
    CMF (20d)-0.059

    Volume Metrics

    Avg Vol (20d)2.8M
    Vol Ratio1.0x
    VWMA (20d)$18.39

    Pivot Points

    R3$17.84
    R2$17.54
    R1$17.02
    Pivot Point$16.72
    S1$16.20
    S2$15.90
    S3$15.38

    Advanced Oscillators

    TSI-19.02
    Ultimate Osc48.8
    KST-123.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$401.25M$730.80M$442.93M$399.36M$611.09M$744.86M$658.41M$467.17M$362.93M$413.46M$396.78M$331.82M
    Cost of Revenue$0$0$398.71M$0$0$0$132.30M$0$0$0$44.18M$0
    Gross Profit$401.25M$730.80M$442.93M$399.36M$611.09M$744.86M$658.41M$467.17M$362.93M$413.46M$396.78M$331.82M
    Operating Expenses$387.96M$372.37M$854.52M$502.75M$495.51M$1.05B$496.73M$444.98M$363.63M$378.56M$372.16M$352.66M
    R&D$91.26M$153.96M$325.34M$218.89M$204.39M$773.45M$199.95M$224.48M$179.69M$200.40M$195.52M$194.30M
    SG&A$107.60M$108.95M$128.30M$91.89M$137.90M$133.63M$163.87M$128.20M$138.80M$127.00M$131.70M$120.89M
    Operating Income$13.29M$358.43M$-411,583,000$-103,389,000$115.58M$-300,386,000$161.68M$22.20M$-701,000$34.91M$24.63M$-20,842,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$15.04M$15.26M$0$138.61M$0$83.13M$0$0$0$0$0$0
    Income Before Tax$-1,749,000$343.17M$-278,296,000$-194,049,000$153.64M$-383,518,000$171.74M$34.01M$13.58M$41.45M$40.37M$-33,174,000
    Income Tax Expense$3.14M$12.21M$4.55M$-14,102,000$-43,254,000$63.99M$12.69M$395,000$7.12M$5.33M$-5,284,000$7.76M
    Net Income$-4,890,000$330.96M$-282,847,000$-179,947,000$196.89M$-447,508,000$159.05M$33.61M$6.46M$36.12M$45.66M$-40,937,000
    EBITDA$8.66M$353.77M$-428,518,000$-36,986,000$164.48M$-373,540,000$182.20M$43.81M$22.30M$50.19M$51.74M$-22,246,000
    EBIT$-1,749,000$343.17M$-433,771,000$-55,436,000$153.64M$-383,518,000$171.74M$34.01M$13.58M$41.45M$40.37M$-33,174,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SRPT

    News

    Sarepta Therapeutics (SRPT) Could Be 22% Undervalued Following SRP 1003 Preclinical Data

    Sarepta Therapeutics (SRPT) recently released fresh preclinical data for its SRP-1003 program, demonstrating significant knockdown of pathogenic DMPK RNA in myotonic dystrophy type 1 models. Despite the positive data...

    Simply Wall Street•10/15/26•Somewhat-Bullish

    Sarepta presents DM1 data as Sarepta Therapeutics stock trades at EUR 15.03

    Sarepta Therapeutics (SRPT) presented new preclinical data for SRP-1003, showing up to 80% knockdown of pathogenic DMPK messenger RNA for myotonic dystrophy type 1...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

    Sarepta Therapeutics (NASDAQ: SRPT) announced new preclinical data for SRP-1003, their investigational siRNA program for Myotonic Dystrophy Type 1 (DM1)...

    Yahoo Finance•10/14/26•Bullish

    Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

    Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Sarepta Therapeutics (SRPT) with a price target of $18.00. This follows similar Sell ratings from other analysts...

    The Globe and Mail•10/10/26•Somewhat-Bearish

    SAREPTA THERAPEUTICS, INC. : RBC CUTS TARGET PRICE TO $17 FROM $19

    RBC Capital has adjusted its price target for Sarepta Therapeutics, Inc. (SRPT), reducing it to $17 from the previous $19. This revision suggests a change in the firm's outlook or valuation for the biopharmaceutical...

    Moomoo•10/9/26•Bearish

    SRPT Valuation and Fair Value

    P/E
    -129.5x
    Forward P/E
    19.2x
    P/FCF
    21.7x
    PEG
    159.3x
    P/B
    1.2x
    See GNG's fair value

    SRPT Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    13.0%
    Net margin
    -6.9%
    ROIC
    -6.2%
    ROE
    -9.5%
    FCF margin
    4.1%
    FCF yield
    4.6%

    SRPT Competitors

    CompanyTicker
    Xeris Pharmaceuticals IncXERS
    Palvella Therapeutics, IncPVLA
    Galapagos NV ADRGLPG
    Vir Biotechnology IncVIR
    Mineralys Therapeutics, Inc. Common StockMLYS
    Xencor IncXNCR
    Surgery Partners IncSGRY
    Sonida Senior Living IncSNDA

    Sector: Healthcare

    SRPT Analyst Ratings

    Consensus
    Hold
    Analysts
    24
    Strong Buy
    0
    Buy
    7
    Hold
    12
    Sell
    3
    Strong Sell
    2

    SRPT Bull Case vs Bear Case

    Bear case

    • SRPT has a -6.9% net profit margin.
    • SRPT's quarterly revenue changed -34.3% year over year.

    SRPT Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -30.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.36
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 5 down

    Frequently Asked Questions About SRPT

    Does SRPT pay dividends?

    Sarepta Therapeutics Inc (SRPT) does not currently pay a regular dividend.

    What is SRPT's market cap?

    Sarepta Therapeutics Inc (SRPT) has a market capitalization of $1.77B with a current stock price of $16.83.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In